Evidence map›Paper›PMID 39403674›Full record

ArticleJAC-antimicrobial resistance2024

Anthony Nsojo, Christopher Mbotwa, Linus Rweyemamu, Godlove Mbwanji, Frank Wilson, Lutengano George, Davance Mwasomola, Clement N Mweya, Issakwisa Mwakyula

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07393308 (Enhancing the Optimization of Empirical Antibiotic Therapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07393308 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Enhancing the Optimization of Empirical Antibiotic Therapy: Development and Implementation of Mobile Antibiograms in Tertiary Hospitals in Tanzania

TypeinterventionalSponsorMuhimbili University of Health and Allied SciencesRan2026 to 2028Enrolled300ConditionsAntimicrobial Prescribing Practices, Antimicrobial Resistance (AMR)ArmsMobile antibiogram application, standard of care
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anthony NsojoResearch Unit, Mbeya Zonal Referral Hospital, P. O. Box 419, Mbeya, Tanzania.
Christopher MbotwaMbeya College of Health and Allied Sciences, University of Dar es Salaam, P. O. Box 608, Mbeya, Tanzania.
Linus RweyemamuMbeya College of Health and Allied Sciences, University of Dar es Salaam, P. O. Box 608, Mbeya, Tanzania.
Godlove MbwanjiResearch Unit, Mbeya Zonal Referral Hospital, P. O. Box 419, Mbeya, Tanzania.
Frank WilsonResearch Unit, Mbeya Zonal Referral Hospital, P. O. Box 419, Mbeya, Tanzania.
Lutengano GeorgeResearch Unit, Mbeya Zonal Referral Hospital, P. O. Box 419, Mbeya, Tanzania.
Davance MwasomolaResearch Unit, Mbeya Zonal Referral Hospital, P. O. Box 419, Mbeya, Tanzania.
Clement N MweyaMbeya College of Health and Allied Sciences, University of Dar es Salaam, P. O. Box 608, Mbeya, Tanzania.
Issakwisa MwakyulaResearch Unit, Mbeya Zonal Referral Hospital, P. O. Box 419, Mbeya, Tanzania.ORCID https://orcid.org/0000-0003-2460-4282

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In Tanzania, ceftriaxone is one of the most commonly prescribed antibiotics. However, there is quite a significant variation in cost for numerous ceftriaxone brands, leading to the perception that pricier options are more effective. Yet, limited empirical data support this perception. Methods: Five ceftriaxone brands with a wide price range were tested Results: All brands were comparable at all tested concentrations, with peak inhibition above 1.95 mg/L. Conclusions: Despite significant price disparities, low-cost and high-cost ceftriaxone brands demonstrated similar

Identifiers

PMID39403674
PMCPMC11472144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.